Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Wild-type interleukin-2 (IL-2) demonstrates anti-tumor immunity but causes significant toxicity, primarily vascular leak syndrome (VLS) and regulatory T cell (Treg) expansion.
• Previous attempts to separate IL-2's therapeutic potency from its toxicity in clinical settings have been unsuccessful.

Purpose of the Study:

• To investigate if combining IL-2 with IL-10 can mitigate IL-2-induced toxicity while preserving its anti-tumor immune activation capabilities.
• To evaluate a novel IL-2/IL-10 fusion molecule (DK2¹⁰) for targeted delivery and efficacy in cancer models.

Main Methods:

• Utilized human primary cells, mouse models, and non-human primates to assess cytokine interactions and toxicity profiles.
• Employed a novel fusion molecule, DK2¹⁰, targeting epidermal growth factor receptor (EGFR) via an anti-EGFR single-chain variable fragment (scFV).
• Evaluated T cell and natural killer (NK) cell activation, interferon-gamma (IFNγ) production, and anti-tumor function in syngeneic murine tumor models.

Main Results:

• The combination of IL-2 and IL-10 prevented peripheral inflammatory toxicity and limited Treg accumulation.
• DK2¹⁰ demonstrated potent activation of T cells and NK cells, leading to IFNγ-dependent anti-tumor effects.
• The fusion molecule effectively elicited anti-tumor immunity without the dose-limiting toxicities associated with traditional IL-2 therapy.

Conclusions:

• Combining IL-2 with IL-10 successfully uncouples toxicity from immune activation, offering a promising strategy for cancer immunotherapy.
• The DK2¹⁰ fusion molecule represents a novel therapeutic approach that achieves potent anti-tumor responses with an improved safety profile.
• This approach leads to a balanced and pleiotropic anti-tumor immune response, potentially overcoming limitations of current immunotherapies.